Abstract. Eleven patients with active acromegaly were treated with 10\p=n-\20 mg bromocriptine daily for a period of 6\p=n-\9 months. The clinical response was evaluated by a 'clinical and metabolic improvement score'. The biochemical response was evaluated by measurement of both the mean plasma growth hormone (GH) level during the day and the somatomedin-C (Sm-C) concentration.
Bromocriptine treatment induced preferentially a reduction of little GH. There was a very good correlation between the decrease of little GH and total GH, and both were significantly correlated with the clinical response.
The correlation between the decrease of Sm-C values and that of little and total GH as well as between the decrease of Sm-C and the clinical response was poor.
It is concluded that a) measurement of little GH is not superior to the determination of total GH in the assessment of disease activity of bromocriptine treated acromegalic patients; b) both methods are superior to the measurement of plasma Sm-C levels; c) clinical response out of proportion ot the fall of total GH which can be explained by a preferential reduction of little GH, has not been observed in our investigations.
It is well established that circulating GH levels do not always correlate with the clinical activity of acromegaly (Kanis et al. 1974 ; Mims & Bethuna 1974) . It has been suggested that somatomedin-C (Sm-C) concentrations correlate better with clinical status than does plasma GH (Clemmons et al. 1979; Wass et al. 1982) , although this has not been found by others (Moses et al. 1981 ; Stonesifer et al. 1981) .
The biologically most active monomeric form of GH (little GH) has a higher radioreceptor activity than larger molecular forms, and in acromegalics this difference is even greater than in normal subjects (Gorden et al. 1976 ). It could therefore be expected that little GH would correlate better with clincial status and perhaps also with Sm-C than total GH.
Chronic treatment with the dopamine agonist bromocriptine has led to a distinct clinical im¬ provement and a reduction of plasma GH levels in the majority of patients with active acromegaly (Sachdev et al. 1975; Belforte et al. 1977; Schwinn et al. 1977; Wass et al. 1977 Wass et al. , 1982 Nortier et al. 1984) . A preferential decrease of little GH has been reported during chronic bromocriptine therapy (Besser et al. 1976; Benker et al. 1979 ). In one study evidence was found for an increase of the clearance of monomeric GH by bromocriptine (Maneschi et al. 1978 (Nortier et al. 1984) . The lower limit of detection was approximately 0.5 mU/1. Intra-and inter-assay variations were 6 and 7.9% (n = 31), respectively. All samples from each patient were measured in the same assay. All values have been expressed in units of the First International Refe¬ rence Preparation (MRC 66/217) .
Somatomedin-C levels were measured by radioim¬ munoassay by Endocrine Sciences, Tarzana, California (Furlanetto et al. 1977) . For subjects aged 26-85 years (n = 38) the upper level of normal is 1.73 U/ml (1.05 + 2 SD).
Fractionations were carried out at 4°C on a Sephadex G-100 column 85 x 1.5 cm, at a flow rate of 7.6 or 8.6 ml/h using a peristaltic pump, and an automatic fraction Since, particularly in acromegalie patients, little GH is known to have a higher radioreceptor acti¬ vity than larger molecular forms of GH (Gorden et al. 1976) , it has been suggested that the somatome¬ dins, particularly Sm-C, correlate better with little GH than with total GH (Moses et al. 1981; Wass et al. 1982) , and that the same holds for the clinical activity of acromegaly.
Our results do not support this supposition. Ghange of little GH did not correlate better with change of Sm-C than that of total GH. The correla¬ tion with clincial response was about the same whether little or total GH was used.
The situation that a decrease in little GH is partially or completely compensated by an increase in big-big or big GH as has been described by Benker et al. (1979) appears to be an exception in the group of patients we investigated. It has been observed in some patients that the degree of clini¬ cal improvement is greater than would be expected from the apparent reduction in circulating GH (Sachdev et al. 1975; Belforte et al. 1977; Wass et al. 1977 Wass et al. , 1982 . This discrepancy has been explained in various ways. The most important mechanisms Table 2 ). In these patients Sm-C levels did not decrease and no selec¬ tive reduction of little GH was found.
